津药药业：关于子公司收到药品GMP符合性检查结果的公告

Core Viewpoint - Tianjin Pharmaceutical Industry announced that its subsidiary, Tianjin Yaohe Pharmaceutical Co., Ltd., has passed the GMP compliance inspection for its eye drop production line, which has a designed capacity of 20 million bottles per year and focuses on the domestic first generic of difluprednate eye drops, projected to achieve global sales of $25 million in 2024 [1]. Group 1 - The production line has a designed capacity of 20 million bottles per year [1]. - The main product is the domestic first generic difluprednate eye drops, used for postoperative anti-inflammatory analgesia [1]. - The projected global sales for 2024 are $25 million [1].